IGF-1 LR3 — Published Research

IGF-1 LR3 has markedly reduced affinity for IGF binding proteins (IGFBPs 1-6), which normally sequester >95% of circulating IGF-1. The Glu³→Arg³ substitution disrupts a critical residue in the IGFBP binding domain, reducing IGFBP-3 affinity by approximately 1000-fold. The 13-amino-acid N-terminal extension further decreases IGFBP interaction. These modifications result in higher free IGF-1 concentrations when LR3 is used compared to equimolar native IGF-1, enhancing receptor occupancy and biological potency per unit mass.

Francis GL et al. “Insulin-like growth factor 1 in a growth retardation syndrome.” Lancet. 1992. PubMed

IGF-1 LR3 binds to the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase. Ligand binding induces receptor autophosphorylation and recruitment of IRS-1/2 adaptor proteins. This activates two major downstream cascades: (1) PI3K/Akt pathway, promoting glucose uptake, protein synthesis (via mTOR), and cell survival; (2) Ras/MAPK pathway, promoting cell proliferation. IGF-1 LR3 shows equivalent IGF-1R binding affinity and signaling potency to native IGF-1 despite the structural modifications, confirming that the IGFBP-binding domain is distinct from the receptor-binding domain.

Siddle K. “Signalling by insulin and IGF receptors: supporting acts and new players.” J Mol Endocrinol. 2011. PubMed

IGF-1 LR3 is widely used as a serum-free cell culture supplement due to its extended stability and reduced IGFBP sequestration. In 3T3-L1 adipocyte differentiation models, IGF-1 LR3 promoted glucose uptake and GLUT-4 translocation via PI3K-dependent mechanisms. CHO and hybridoma cell cultures showed enhanced proliferation with LR3 supplementation compared to native IGF-1. The extended half-life (approximately 20–30 hours vs. 10–20 minutes for native IGF-1) reduces required supplementation frequency.

Tomas FM et al. “IGF-I and especially IGF-I variants are anabolic in dexamethasone-treated rats.” Am J Physiol. 1993. PMC